--- title: "Solid Biosciences (SLDB) news: offering" url: "https://aibio.space/companies/solid-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SLDB offering news: Solid Biosciences adds sales program of up to $200,000,000 with Jefferies. Solid Biosciences Inc. (NASDAQ: SLDB), United States." --- SLDB Solid Biosciences Inc. NASDAQ · United States # Solid Biosciences (SLDB) news SLDB offering news Financings · 2026-08-06 ## [Solid Biosciences adds sales program of up to $200,000,000 with Jefferies](https://aibio.space/news/solid-biosciences-adds-sales-program-up-200-000-000-jefferies/) Solid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price. ## Latest Solid Biosciences news 1. 2026-06-10 Listings [Solid Biosciences holders approve doubling authorized shares to 480,000,000](https://aibio.space/news/solid-biosciences-holders-approve-doubling-authorized-shares-480-000/) Solid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against. 2. 2026-06-05 Financings [Solid Biosciences updates resale prospectus to add selling stockholders](https://aibio.space/news/solid-biosciences-updates-resale-prospectus-add-selling-stockholders/) Solid Biosciences filed a prospectus supplement on June 5, 2026 that adds holders who bought shares from existing selling stockholders. Several holders in the table are offering their entire stake, and the company says it does not know when or in what amounts they will sell. 3. 2026-03-06 Financings [Solid Biosciences agrees to $240.0 million private placement at $5.61 per share](https://aibio.space/news/solid-biosciences-agrees-240-0-million-private-placement-5-61-share/) Solid Biosciences agreed to sell 14,973,257 shares at $5.61 and pre-funded warrants for 27,807,482 shares, for about $240.0 million gross. Its year-end 2025 cash figure is a preliminary, unaudited estimate, and the company says the deal extends runway into the first half of 2028. ## Solid Biosciences at a glance - **Ticker**: SLDB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $377.7 million ### Related companies - [Fractyl Health](https://aibio.space/companies/fractyl-health/) NASDAQ: GUTS - [Altimmune](https://aibio.space/companies/altimmune/) NASDAQ: ALT - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) NASDAQ: GENB - [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) NASDAQ: SXTP - [United Therapeutics](https://aibio.space/companies/united-therapeutics/) NASDAQ: UTHR - [Cue Biopharma](https://aibio.space/companies/cue-biopharma/) NASDAQ: CUE - [Caribou Biosciences](https://aibio.space/companies/caribou-biosciences/) NASDAQ: CRBU - [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) NASDAQ: KRYS ### Also on NASDAQ - [BioCardia](https://aibio.space/companies/biocardia/) BCDA - [Invivyd](https://aibio.space/companies/invivyd/) IVVD - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) GLSI - [VivoSim Labs, INC.](https://aibio.space/companies/vivosim-labs/) VIVS - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) RLAY - [Connect Biopharma Holdings](https://aibio.space/companies/connect-biopharma/) CNTB ## Solid Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$140.3 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | [$96.4 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | | Cash from operations | [-$156.3 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | [-$100.0 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | | Cash and equivalents | [$59.9 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526337935/) | [$80.2 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | | Short-term investments | [$128.0 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526337935/) | [$68.7 million](https://www.sec.gov/Archives/edgar/data/1707502/000119312526115928/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $159.4 million, plus short-term investments of $218.3 million, $377.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Solid Biosciences Has Solid Biosciences raised money recently? Our latest story on this, dated Aug 6, 2026: "Solid Biosciences adds sales program of up to $200,000,000 with Jefferies". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/solid-biosciences-adds-sales-program-up-200-000-000-jefferies/). What is the ticker symbol of Solid Biosciences? Solid Biosciences Inc. trades under the ticker SLDB on NASDAQ. Where is Solid Biosciences listed? Solid Biosciences Inc. is listed on NASDAQ. What is the SEC CIK of Solid Biosciences? The SEC Central Index Key (CIK) for Solid Biosciences Inc. is 1707502. Its filings are on SEC EDGAR. How many shares does Solid Biosciences have outstanding? 107,225,238 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Solid Biosciences listed under? Our directory records Solid Biosciences Inc. under United States. What does Solid Biosciences do? Our directory classifies Solid Biosciences Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Solid Biosciences? The ISIN recorded for Solid Biosciences Inc. is US83422E2046. Does aibio.space cover Solid Biosciences? aibio.space lists Solid Biosciences Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Solid Biosciences incorporated? SEC records list its state or country of incorporation as DE. How much does Solid Biosciences spend on research and development? $140.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Solid Biosciences have? $377.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Solid Biosciences (SLDB) stock news? Our latest story on Solid Biosciences, dated Aug 6, 2026: "Solid Biosciences adds sales program of up to $200,000,000 with Jefferies". Solid Biosciences filed a prospectus supplement for up to $200,000,000 of at-the-market stock sales through Jefferies, replacing a prior $85,000,000 program. The filing says buyers would face dilution of about $4.30 per share at an assumed $8.73 price. [Source](https://aibio.space/news/solid-biosciences-adds-sales-program-up-200-000-000-jefferies/). How long will Solid Biosciences's cash last? From our story of Mar 6, 2026: The company estimates that the net proceeds, together with its existing cash and securities, will fund its operating expenses and capital expenditure requirements into the first half of 2028. [Source](https://aibio.space/news/solid-biosciences-agrees-240-0-million-private-placement-5-61-share/). Is Solid Biosciences at risk of delisting? Our latest listing story, dated Jun 10, 2026: "Solid Biosciences holders approve doubling authorized shares to 480,000,000". Solid Biosciences stockholders voted at the June 10, 2026 annual meeting to double authorized common stock to 480,000,000 shares. The vote drew 893,360 votes against, and the say-on-pay vote drew 6,203,634 against. [Source](https://aibio.space/news/solid-biosciences-holders-approve-doubling-authorized-shares-480-000/). ## Investor discussion: Solid Biosciences Members talk about Solid Biosciences (SLDB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Solid Biosciences, newest first. Each line links the filing it comes from. 1. 2026-08-06 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312526338410/d360115d424b5.htm) 2. 2026-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/sldb-20260610.htm) 3. 2026-06-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B7. [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312526259503/d149984d424b7.htm) 4. 2026-03-19 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312526116158/d120326ds3.htm) 5. 2026-03-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312526096709/d81855d8k.htm) 6. 2025-06-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1707502/000095017025086215/sldb-20250612.htm) 7. 2025-05-15 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1707502/000095017025072786/atm_prospectus_-_05.15._.htm) 8. 2025-03-06 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312525048487/d840154ds3.htm) 9. 2025-02-18 Financings Reported a financing. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1707502/000119312525028146/d916580d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SLDB on TradingView](https://www.tradingview.com/symbols/NASDAQ-SLDB/). ## SEC filings and registration - **SEC name**: Solid Biosciences Inc. - **CIK**: 1707502 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: SLDB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 500 RUTHERFORD AVENUE, CHARLESTOWN, MA, 02129 - **Phone**: 617-337-4680 - **Shares outstanding**: 107,225,238 as of 2026-08-04 (10-Q filed 2026-08-06) - **Former names**: Solid Biosciences, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312526338438/d177624d8k.htm) filed 2026-08-06 - [424B5](https://www.sec.gov/Archives/edgar/data/1707502/000119312526338410/d360115d424b5.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1707502/000119312526337935/sldb-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/sldb-20260610.htm) filed 2026-06-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1707502/000119312526219337/sldb-20260331.htm) filed 2026-05-12 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1707502/000119312526173642/sldb-20260422.htm) filed 2026-04-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312526151259/sldb-20260410.htm) filed 2026-04-10 - [S-3](https://www.sec.gov/Archives/edgar/data/1707502/000119312526116163/d125122ds3.htm) filed 2026-03-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001707502), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Solid Biosciences Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SLDB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Solid Biosciences Inc. - **Ticker**: SLDB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US83422E2046 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SLDB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/solid-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Solid Biosciences (SLDB) news: offering", 2026-10-31, https://aibio.space/companies/solid-biosciences/